Daclatasvir plus sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison

被引：6
|
作者：
Swallow, Elyse [1 ]
Song, Jinlin [1 ]
Yuan, Yong [2 ]
Kalsekar, Anupama [2 ]
Kelley, Caroline [1 ]
Mu, Fan [1 ]
Kim, Soomi [1 ]
Noviello, Stephanie [2 ]
Signorovitch, James [1 ]
机构：
[1] Anal Grp Inc, 111 Huntington Ave,10th Floor, Boston, MA 02199 USA
[2] Bristol Myers Squibb Co, 100 Nassau Pk Blvd, Princeton, NJ 08540 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2016年 / 5卷 / 02期
关键词：
daclatasvir; hepatitis C genotype 3; matching-adjusted indirect comparison; peginterferon; ribavirin; sofosbuvir; SUSTAINED VIROLOGICAL RESPONSE; PEGINTERFERON ALPHA-2A; VIRUS; RIBAVIRIN; INFECTION;
D O I：
10.2217/cer.15.49
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
To compare the efficacy and tolerability of daclatasvir and sofosbuvir (DCV + SOF) versus SOF and ribavirin (SOF + R) and versus peginterferon-alfa plus ribavirin (A/R) in patients infected with hepatitis C genotype 3. Patients & methods: Clinical trials of SOF + R or A/R were identified in systematic literature reviews. The DCV+ SOF population was adjusted via propensity score weighting to match average baseline characteristics to those reported for the comparator regimens. Results: The SVR12 rate was similar between DCV + SOF and SOF + R, and significantly higher with DCV + SOF than A/R. Rates of discontinuation due to AEs were similar or significantly lower in patients treated with DCV + SOF than SOF + R or A/R. Conclusion: With its high efficacy and improved tolerability, DCV + SOF is an important treatment for hepatitis C genotype 3.
引用
收藏
页码：129 / 139
页数：11
相关论文
共 50 条
  • [21] Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies
    Kahveci, Ali Murat
    Tahan, Veysel
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2016, 27 (01): : 89 - 90
  • [22] Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection
    Llenas-Garcia, Jara
    Padilla, Sergio
    Masia, Mar
    Gutierrez, Felix
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2018, 36 (07): : 457 - 457
  • [23] Pembrolizumab plus Chemo versus Atezolizumab plus Chemo plus /-Bevacizumab for First-Line Nonsquamous NSCLC: A Matching-Adjusted Indirect Comparison
    Halmos, B.
    Burke, T.
    Kalyvas, C.
    Vandormael, K.
    Frederickson, A.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S24 - S24
  • [24] Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis
    Cohan, Stanley
    Tencer, Tom
    Arndorfer, Stella
    Zhu, Xuelian
    Zivkovic, Marko
    Kumar, Jinender
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [25] Matching-Adjusted Indirect Comparison between Personalized Prophylaxis with Simoctocog Alfa Versus Standard Prophylaxis with Emicizumab in Adults with Hemophilia a
    Kessler, Craig
    Corrales-Medina, Fernando F.
    Mannucci, Pier Mannuccio
    Tarantino, Michael D.
    BLOOD, 2023, 142
  • [26] Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
    Garcia-Foncillas, J.
    Bokemeyer, C.
    Italiano, A.
    Keating, K.
    Paracha, N.
    Fellous, M.
    Marian, M.
    Fillbrunn, M.
    Gao, W.
    Ayyagari, R.
    Lassen, U. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S401 - S401
  • [27] Comparative effectiveness of ozanimod versus dimethyl fumarate: results of a matching-adjusted indirect comparison
    Cohan, S.
    Kumar, J.
    Arndorfer, S.
    Zhu, X.
    Zivkovic, M.
    Tencer, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 140 - 140
  • [28] Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection
    Sundaram, Vinay
    Kowdley, Kris V.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (01) : 13 - 20
  • [29] Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison
    Moreau, Philippe
    Hebraud, Benjamin
    Facon, Thierry
    Leleu, Xavier
    Hulin, Cyrille
    Hashim, Mahmoud
    Hu, Yannan
    Caillot, Denis
    Benboubker, Lofti
    Zweegman, Sonja
    Merz, Maximilian
    Weisel, Katja
    Salwender, Hans
    Mai, Elias K.
    Goldschmidt, Hartmut
    Bertsch, Uta
    Vanquickelberghe, Veronique
    Kampfenkel, Tobias
    Boer, Carla de
    Krotneva, Stanimira
    Proskorovsky, Irina
    He, Jianming
    Lam, Annette
    Lee, Charlene
    Cote, Sarah
    Sonneveld, Pieter
    IMMUNOTHERAPY, 2021, 13 (02) : 143 - 154
  • [30] Matching-Adjusted Indirect Comparison of Personalized Prophylaxis with Simoctocog Alfa Versus Standard Prophylaxis with Efanesoctocog Alfa in Adults with Severe Hemophilia a
    Kessler, Craig
    Corrales-Medina, Fernando F.
    Mannucci, Pier Mannuccio
    Tarantino, Michael D.
    BLOOD, 2023, 142
12345